Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity

Cancer Research

Volumn 69, Issue 5, 2009, Pages 1910-1915

  Arora, Sonia ^a   Wang, Xin I ^a   Keenan, Susan M ^b   Andaya, Christina ^a   Zhang, Qiang ^a   Peng, Youyi ^a   Welsh, William J ^a,c  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b UNIVERSITY OF NORTHERN COLORADO   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 5 (3 (3,4,5 TRIMETHOXYPHENYL) 4H 1,2,4 TRIAZOLE 4 YL) 1H INDOLE; COLCHICINE; PACLITAXEL; T 115; TRIAZOLE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE; ANTINEOPLASTIC AGENT; TUBULIN MODULATOR;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG COMPETITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAXIMUM TOLERATED DOSE; MICROTUBULE ASSEMBLY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; SKIN FIBROBLAST; XENOGRAFT; ANIMAL; BINDING SITE; CELL DIVISION; CELL LINE; CELL SURVIVAL; CHEMISTRY; COLORECTAL TUMOR; DRUG EFFECT; DRUG SCREENING; MALE; METABOLISM; MICROTUBULE; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL DIVISION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COLCHICINE; COLORECTAL NEOPLASMS; G2 PHASE; HUMANS; MALE; MICE; MICROTUBULES; PROSTATIC NEOPLASMS; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 62449302405     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0877     Document Type: Article

References (24)

1. Wittmann T, Hyman A, Desai A. The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol 200.1;3:E28-34.
2. Lowe J, Li H, Downing KH, Nogales E. Refined structure of a [i-tubulin at 3.5 A resolution. J MoI Biol 2001:313:1045-57.
3. Inoue S, Fuseler J, Salmon ED, Ellis GW. Functional organization of mitotic microtubules. Physical chemis-try of the in viva equilibrium, system. Biophys J 1975;15: 725-744.
4. Jordan MA, Wendell K, Gardiner S, Deny WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotlc cell death. Cancer Res 1996; 56:816-825.
5. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. MoI Med 1995; 1: 506-26.
6. Takáno Y, Okudaira M, Harmon BV. Apoptosis induced by microtubule disrupting drugs in. cultured human lymphoma cells. Inhibitory effects of phorbol ester and zinc sulphate. Pathol Res Pract 1993:189:. 197-203.
7. Tsukidate K, Yamamoto K, Snyder JW, Färber JL. Microtubule antagonists activate programmed cell death (apoptosis) in cultured rat hepatocytes. Am J Pathol 1993;143:918-925.
8. Halt WN, Rubin E, Goodin S. Tubulin-targeting agents. Cancer Chemother Biol Response Modif 2005;22:35-59.
9. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-265
10. Ohsumi K, Nakagawa R, Fukuda Y, et al. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem 1998;41:3022-3032.
11. Pettit GR, Rhodes MR, Herald DL, et al. Antineoplas-tic agents 393. Synthesis of the frans-isomer of combretastatin A-4 prodrug Anticancer Drug Des 1998;13:981-993.
12. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin Inhibitor combretastatin A-4. Experientia 1989;45:209-211
13. Cavaletti G, Cavallettl E, Oggloni N, et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 2000;21:389-393.
14. Windebank AJ. Chemotherapeutic neuropathy. Curr Opin Neurol 1999;12:565-571.
15. Dumontet C, Slkic BI. Mechanisms of action, of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol I999;17: 1061-1070.
16. Zhang Q, Peng Y, Wang XI, Keenan SM, Arora S, Welsh WJ. Highly potent trlazole-based tubulin poly-merization, inhibitors. J Med Chem 2007;50:749-754
17. Ravelli RB, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 2004;428:198-202.
18. Islam MN, Iskander MN. Microtubulln binding sites as target for developing anticancer agents. Mini Rev Med Chem. 20044.1077-104.
19. Pettit GR, Toki BE, Herald DL, et al. Antineoplastic agents. 410. Asymmetric hydroxylation of trans-com-bretastatin A-4. J Med Chem 1999;42:1459-1465.
20. Bitton RJ, Figg WD, Reed E. A preliminary risk-benefit assessment of paclitaxel. Drug Saf 1995;12:196-208.
21. Cole SP, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. BioEssays 1998:20:931-940.
22. Simoni D, Grisolla G, Giannini G, et al. Heterocyclic and phenyl double-bond-locked combretastatin ana-logues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. J Med Chem 2005:48: 723-736.
23. Kanthou C, Greco O, Stratford A, et al. The tübulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in. mitosis and induces mitotic cell death. Am J Pathol 2004165:1401-11.
24. Shoemaker RH. The NCI.60 human tumour cell line anticancer drug screea Nat Rev Cancer 2006;6:813-23.